Gold, I told Terry about Constabpharma several weeks ago and he said he relayed an email to Dr Moro and they would be checking into possible patent infringement, I was more interested in a collaboration or buying them out at some point, obviously when we have money. They are also a Canadian company. The response is that Dr Moro was aware of their progress and would not rule out something with them.
Is it me or is this just more of the same. No follow up, more dilution, wasting money on penny newsletters, low volume, and share price drifting lower. We need to know when the company will expect Recaf to hit the market. It is time for a shareholder update if management has any consideration for its shareholders.
I am disappointed in no real media coverage. We have something exclusive and something everyone in the world would be intersted in knowing about. What is so hard about picking up the phone and bombarding the media. I am so angry they are still making the same mistakes and need to put an end to paying for coverage and absolutely no effort to contact any media. This is a major failure to execute properly by management and I am afraid they will never understand the share price is where it is at, because of their failure to take the high road. Anyone I have personally told about Biocurex has always asked me if they are on the stock exchange and was excited about the technology.
I will continue to be patient, but I won't feel management has done its job until I see us presenting at more oncology meetings and have unpaid for media coverage. There is nothing wrong with an update about Abbott, the ISOBM, or any negotiations. They must have their heads way up their *** if they don't realize everyone is suffering monetarily as a result of their waste of money issuing shares to small cap as they continue to sell. I would rather have them spend the money on hiring more employees or a newer facility for our lab.
AI
